Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MYO7B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MYO7B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MYO7B_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
GO:0051650 | Colorectum | AD | establishment of vesicle localization | 57/3918 | 161/18723 | 1.47e-05 | 3.15e-04 | 57 |
GO:0051648 | Colorectum | AD | vesicle localization | 59/3918 | 177/18723 | 7.83e-05 | 1.25e-03 | 59 |
GO:0030048 | Colorectum | AD | actin filament-based movement | 44/3918 | 127/18723 | 2.31e-04 | 2.99e-03 | 44 |
GO:0099515 | Colorectum | AD | actin filament-based transport | 12/3918 | 21/18723 | 3.02e-04 | 3.62e-03 | 12 |
GO:0030050 | Colorectum | AD | vesicle transport along actin filament | 11/3918 | 19/18723 | 4.66e-04 | 5.15e-03 | 11 |
GO:0030705 | Colorectum | AD | cytoskeleton-dependent intracellular transport | 60/3918 | 195/18723 | 7.56e-04 | 7.59e-03 | 60 |
GO:00070151 | Colorectum | SER | actin filament organization | 134/2897 | 442/18723 | 1.39e-15 | 5.70e-13 | 134 |
GO:00516561 | Colorectum | SER | establishment of organelle localization | 100/2897 | 390/18723 | 1.11e-07 | 6.79e-06 | 100 |
GO:00300481 | Colorectum | SER | actin filament-based movement | 38/2897 | 127/18723 | 2.80e-05 | 7.56e-04 | 38 |
GO:00995151 | Colorectum | SER | actin filament-based transport | 11/2897 | 21/18723 | 9.28e-05 | 1.98e-03 | 11 |
GO:00300501 | Colorectum | SER | vesicle transport along actin filament | 10/2897 | 19/18723 | 1.86e-04 | 3.43e-03 | 10 |
GO:00516501 | Colorectum | SER | establishment of vesicle localization | 42/2897 | 161/18723 | 3.38e-04 | 5.35e-03 | 42 |
GO:00516481 | Colorectum | SER | vesicle localization | 43/2897 | 177/18723 | 1.41e-03 | 1.53e-02 | 43 |
GO:00307051 | Colorectum | SER | cytoskeleton-dependent intracellular transport | 44/2897 | 195/18723 | 5.53e-03 | 4.09e-02 | 44 |
GO:00070152 | Colorectum | MSS | actin filament organization | 146/3467 | 442/18723 | 1.16e-13 | 2.67e-11 | 146 |
GO:00516562 | Colorectum | MSS | establishment of organelle localization | 115/3467 | 390/18723 | 7.30e-08 | 3.67e-06 | 115 |
GO:00300482 | Colorectum | MSS | actin filament-based movement | 44/3467 | 127/18723 | 1.11e-05 | 2.64e-04 | 44 |
GO:00516502 | Colorectum | MSS | establishment of vesicle localization | 51/3467 | 161/18723 | 3.92e-05 | 7.45e-04 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYO7B | SNV | Missense_Mutation | rs371739405 | c.2725N>A | p.Val909Ile | p.V909I | Q6PIF6 | protein_coding | tolerated(0.74) | benign(0) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
MYO7B | SNV | Missense_Mutation | novel | c.3913N>G | p.Leu1305Val | p.L1305V | Q6PIF6 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
MYO7B | SNV | Missense_Mutation | | c.4493N>T | p.Gly1498Val | p.G1498V | Q6PIF6 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR |
MYO7B | SNV | Missense_Mutation | novel | c.4180N>C | p.Glu1394Gln | p.E1394Q | Q6PIF6 | protein_coding | deleterious(0.05) | benign(0.011) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MYO7B | SNV | Missense_Mutation | | c.1667N>T | p.Gly556Val | p.G556V | Q6PIF6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MYO7B | SNV | Missense_Mutation | rs576789048 | c.38N>G | p.Glu13Gly | p.E13G | Q6PIF6 | protein_coding | deleterious(0.01) | benign(0.05) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MYO7B | SNV | Missense_Mutation | rs576789048 | c.38N>G | p.Glu13Gly | p.E13G | Q6PIF6 | protein_coding | deleterious(0.01) | benign(0.05) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MYO7B | SNV | Missense_Mutation | rs576789048 | c.38N>G | p.Glu13Gly | p.E13G | Q6PIF6 | protein_coding | deleterious(0.01) | benign(0.05) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
MYO7B | SNV | Missense_Mutation | | c.1791N>C | p.Leu597Phe | p.L597F | Q6PIF6 | protein_coding | tolerated(0.57) | possibly_damaging(0.588) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
MYO7B | SNV | Missense_Mutation | | c.4426N>A | p.Glu1476Lys | p.E1476K | Q6PIF6 | protein_coding | tolerated(0.07) | benign(0.169) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |